Interleukin-6 inhibition
Interleukin-6 inhibition has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Sep 15, 2026: “Beyond Prognosis: A Systematic Review of the Neutrophil-to-Lymphocyte Ratio as a Modifiable Cardiovascular Biomarker”.
1 paper studies it1 findingUpdated
See all 1 papers on interleukin-6 inhibition
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
- 1 lab in 1 country
What did studies of interleukin-6 inhibition find?
1Studies of interleukin-6 inhibition measured one outcome, neutrophil-to-lymphocyte ratio.
Neutrophil-to-lymphocyte ratio
downin humans1
1 study
Neutrophil-to-lymphocyte ratio
downin humans1
Interleukin-6 inhibition decreases neutrophil-to-lymphocyte ratio in humans (established cardiovascular disease or elevated cardiovascular risk).
“Direct interleukin-6 (IL-6) inhibition produced the clearest dose-dependent reduction in NLR”
Reviewestablished cardiovascular disease or elevated cardiovascular risk
Cureus